MLXIPL/ChREBP Causal Inference Study for Diabetic Kidney Disease

A research article integrating Mendelian randomization, kidney transcriptomics, and experimental validation to identify the transcription factor ChREBP (MLXIPL) as a driver of metabolic remodeling in diabetic kidney disease. The study was authored by Mingliang Liu and published on figshare under a CC-BY-4.0 license in April 2026. The dataset is a 198.0 B DOCX file containing the manuscript.

Use Cases

• Reviewing the integrated causal inference methodology based on two-sample Mendelian randomization.
• Analyzing kidney transcriptomic stratification results based on MLXIPL expression levels.
• Studying network analyses of metabolic and regulatory interactions mentioned in the description.
• Examining experimental validation data from db/db mice and primary proximal tubular epithelial cells.

Strengths

• The study integrates multiple analytical methods: Mendelian randomization, transcriptomics, network analysis, and experimental validation.
• The dataset is openly available under a CC-BY-4.0 license.
• The research includes validation in a non-diabetic UACR stratum and in db/db mouse models.

Limitations

• The dataset is a 198.0 B DOCX file, indicating it is a manuscript rather than raw data tables.
• Row count and column-level documentation are absent; data semantics must be inferred from the text.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

The data was generated through integrated genetic inference, transcriptomic analysis, and experimental biology as described in the manuscript.

Time Range

The temporal coverage of the underlying study is not specified.

Freshness

Last updated 2026-04-15 05:43:04; freshness should be verified.

Geography

The spatial coverage of the underlying study is not specified.